Kymera Therapeutics reported that its first‑in‑class oral STAT6 degrader, KT‑621, achieved deep target degradation and meaningful clinical activity in a 22‑patient, open‑label Phase 1b study of moderate‑to‑severe atopic dermatitis. Median STAT6 degradation reached 94 % in skin and 98 % in blood, while the key Type 2 biomarker TARC fell 74 % and the Eczema Area and Severity Index (EASI) score dropped 63 %.
The biomarker reductions mirror the magnitude of dupilumab’s early‑phase data, suggesting that KT‑621 can deliver biologic‑like efficacy from a once‑daily pill. In addition to TARC, the study reported significant declines in Eotaxin‑3, IL‑31, and IgE, and patients reported marked improvements in itch and quality‑of‑life scores.
Safety data were consistent with the Phase 1a healthy‑volunteer study, with no serious adverse events and a tolerability profile that supports the platform’s oral delivery. The results validate Kymera’s targeted protein‑degradation technology and demonstrate that the drug can achieve deep STAT6 knockdown without compromising safety.
Kymera’s Q3 2025 earnings showed a net loss of $82.2 million, but the company’s cash balance of $978.7 million provides a runway into 2028. The Phase 1b data have generated a strong market reaction, with investors citing the deep degradation and dupilumab‑like efficacy as key drivers of the company’s valuation.
The company plans to launch its BROADEN2 Phase IIb trial in the fourth quarter of 2025 and to begin the BREADTH asthma Phase IIb study in early 2026. With the type 2 inflammatory disease market estimated at over $130 million patients worldwide and an atopic dermatitis market valued at $19.4 billion in 2025, KT‑621 could capture a significant share of the $100 B+ opportunity.
CEO Nello Mainolfi said, “The BroADen study results exceeded our highest expectations and provide a powerful additional validation of our industry‑leading STAT6 degrader program.” Chief Medical Officer Jared Gollob added, “The consistency of the results across all measured endpoints—STAT6 degradation, biomarker reduction, and clinical improvement—underscores the potential of KT‑621 to transform the treatment landscape for type 2 inflammatory diseases.”
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.